These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 26084899)
1. Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment. Yoshida M; Nakao T; Horiuchi M; Ueda H; Hagihara K; Kanashima H; Inoue T; Sakamoto E; Hirai M; Koh H; Nakane T; Hino M; Yamane T Eur J Haematol; 2016 Apr; 96(4):409-16. PubMed ID: 26084899 [TBL] [Abstract][Full Text] [Related]
2. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Tucci A; Ferrari S; Bottelli C; Borlenghi E; Drera M; Rossi G Cancer; 2009 Oct; 115(19):4547-53. PubMed ID: 19562776 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China. Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Tucci A; Martelli M; Rigacci L; Riccomagno P; Cabras MG; Salvi F; Stelitano C; Fabbri A; Storti S; Fogazzi S; Mancuso S; Brugiatelli M; Fama A; Paesano P; Puccini B; Bottelli C; Dalceggio D; Bertagna F; Rossi G; Spina M; Leuk Lymphoma; 2015 Apr; 56(4):921-6. PubMed ID: 25110825 [TBL] [Abstract][Full Text] [Related]
5. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Spina M; Balzarotti M; Uziel L; Ferreri AJ; Fratino L; Magagnoli M; Talamini R; Giacalone A; Ravaioli E; Chimienti E; Berretta M; Lleshi A; Santoro A; Tirelli U Oncologist; 2012; 17(6):838-46. PubMed ID: 22610154 [TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468 [TBL] [Abstract][Full Text] [Related]
7. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations. Ong DM; Ashby M; Grigg A; Gard G; Ng ZY; Huang HE; Chong YS; Cheah CY; Devitt B; Chong G; Loh Z; Mo A; Hawkes EA Br J Haematol; 2019 Oct; 187(1):73-81. PubMed ID: 31206608 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232 [TBL] [Abstract][Full Text] [Related]
10. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly. Khan Y; Brem EA Curr Hematol Malig Rep; 2019 Aug; 14(4):228-238. PubMed ID: 31228094 [TBL] [Abstract][Full Text] [Related]
11. A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. Marchesi F; Cenfra N; Altomare L; Dessanti ML; Mecarocci S; Cerchiara E; Rago A; D'Andrea M; Tomarchio V; Olimpieri OM; Tirindelli MC; Mengarelli A; Petti MC; Avvisati G; Cimino G J Geriatr Oncol; 2013 Jul; 4(3):242-8. PubMed ID: 24070462 [TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285 [TBL] [Abstract][Full Text] [Related]
13. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases. Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613 [TBL] [Abstract][Full Text] [Related]
14. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569 [TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL). Tucci A; Merli F; Fabbri A; Marcheselli L; Pagani C; Puccini B; Marino D; Zanni M; Pennese E; Flenghi L; Arcari A; Botto B; Celli M; Mammi C; Re A; Campostrini G; Tafuri A; Zilioli VR; Cencini E; Sartori R; Bottelli C; Merli M; Petrucci L; Gini G; Balzarotti M; Cavallo F; Musuraca G; Luminari S; Rossi G; Spina M Haematologica; 2023 Apr; 108(4):1083-1091. PubMed ID: 36384247 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review. Jung YH; Woo IS; Han CW Korean J Intern Med; 2015 Sep; 30(5):684-93. PubMed ID: 26354063 [TBL] [Abstract][Full Text] [Related]
17. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062 [TBL] [Abstract][Full Text] [Related]
18. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193 [TBL] [Abstract][Full Text] [Related]
19. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296 [TBL] [Abstract][Full Text] [Related]
20. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]